Placebo for E2/NETA

DRUG2 trials

Sponsors

AbbVie, Myovant Sciences GmbH

Conditions

EndometriosisUterine FibroidsUterine Leiomyoma

Phase 3

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

CompletedNCT03213457

AbbVieEndometriosis

Start: 2017-07-07End: 2023-12-06Updated: 2024-12-20

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

CompletedNCT03751124

Myovant Sciences GmbHUterine Fibroids, Uterine Leiomyoma

Start: 2018-10-16End: 2021-10-20Updated: 2024-06-25

Related Papers

Long-Term Safety of Elagolix With Add-Back in Women With Endometriosis-Associated Pain: 36-Month Results [ID: 1368036]

Obstetrics and Gynecology2023-05-01

Bone Mineral Density Changes Associated With Pregnancy, Lactation, and Medical Treatments in Premenopausal Women and Effects Later in Life.

2021-08-2525 citations